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TO THE EDITOR
Recessive dystrophic epidermolysis
bullosa (RDEB) is a devastating inher-
ited skin disease caused by mutations in
the gene encoding type VII collagen
(Christiano et al., 1993). The condition is
characterized by skin fragility, trauma-
induced skin blistering, and chronic
non-healing wounds (Mellerio et al.,
2007). Patients with RDEB are at
strongly increased risk of developing
aggressive cutaneous squamous cell
carcinoma (SCC), which is the cause
of death by age 45 years in 70% of
individuals with the most severe form of
RDEB (Fine et al., 2009). Potential
similarities between the microenviron-
ment of non-healing wounds and
mucosal epithelia, wherein human
papillomaviruses (HPVs) have been
shown to induce the development of
SCC (Zur Hausen, 2009), led us to
investigate whether HPV infection
could be responsible for the increased
incidence and aggressive nature of
RDEB SCC. The involvement of HPV
in the development of cutaneous SCC
remains controversial, except in the
rare genodermatosis epidermodysplasia
verruciformis, wherein up to 60% of
patients develop SCC containing high
copy numbers of beta-papillomavirus
(b-PV) (Harwood and Proby, 2002), which
may be restricted to a minority of tumor
cells (Dell’Oste et al., 2009). The possi-
bility that HPV are also involved in
RDEB SCC has not been addressed.
HPVs are a diverse group of small
double-stranded DNA viruses that in-
fect squamous epithelial cells. The two
largest genera are alpha-papillomavirus
(a-PV), comprising all HPV genotypes
found in mucosal lesions as well as many
of those associated with benign skin
warts, and b-PV, containing HPV types,
which have most frequently been asso-
ciated with epidermodysplasia verruci-
formis and cutaneous SCC (de Villiers
et al., 2004). Because vaccines against
prevalent high risk mucosal/genital HPV
(HPV16/18) are available and effective
at preventing cancer development
(Zur Hausen, 2009), we tested RDEB
SCC for the presence of 18 high risk
a-PV types using the digene HPV
genotyping reverse hybridization assay
detection kit (Qiagen, Leiden, The
Netherlands). We tested DNA prepared
from 21 separate SCC isolated from
12 RDEB patients as well as DNA
from 39 organ transplant recipient
SCC and 18 immunocompetent SCC
collected for a separate study (Purdie
et al., 2009) with 6 vulval SCC samples
included as positive controls. All DNA
were isolated from frozen tissue col-
lected after informed consent and in
accordance with Helsinki guidelines
following research ethics committee
approval. All cutaneous SCC from
RDEB and non-RDEB individuals were
negative, whereas nine different a-PV
types were detected in the vulval SCC
samples.
Next we tested the presence of b-PV
using the reverse hybridization assay kit
skin (b) HPV detection system (Diassay,
Rijswijk, The Netherlands) (de Koning
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et al., 2006). In addition to the cuta-
neous SCC samples described, we
tested seven peritumoral skin samples
from five of our SCC RDEB patients and
normal uninvolved skin from 11 RDEB
patients who had not yet developed
SCC. As before, all DNA were isolated
from frozen tissue. Data are summar-
ized in Table 1. The overall detection
rate of b-PV in RDEB SCC was 90%
compared with 74% and 78% for organ
transplant recipient SCC and immuno-
competent SCC respectively, with simi-
lar frequencies observed in RDEB
peritumoral and normal skin. As b-PV
infection has been shown to be pre-
valent at low copy number in non-
tumor bearing normal skin and hair
follicles, a role for these viruses is
perhaps more plausible in lesions with
higher viral load (Feltkamp et al.,
2008). We next examined viral load
for b-PV using quantitative PCR as
described (Weissenborn et al., 2010),
Table 1. Percentage of samples positive for b-HPV by reverse hybridization assay with multiple infection indicated
Types most
Number of types detected1
Sample group RHA-positive frequently detected 1 2 3 4 5
OTR SCC (n=39) 74% (29) 23 (9)
15 (7)
5 (4)
93 (4)
31% (9) 28% (8) 21% (6) 3% (1) 17% (5)
IC SCC (n=18) 78% (14) 5 (2)
8 (2)
9 (2)
24 (2)
43% (6) 36% (5) 7% (1) 7% (1) 7% (1)
RDEB SCC (n=21) 90% (19) 23 (6)
12 (4)
15 (4)
8 (3)
24 (3)
37% (7) 37% (7) 11% (2) 5% (1) 11% (2)
RDEB peri-lesional skin; patients with SCC (n=7) 71% (5) 17 (4)
8 (2)
23 (2)
24 (2)
40% (2) 20% (1) — — 40% (2)
RDEB normal skin; patients without SCC (n=11) 82% (9) 23 (8)
49 (5)
17 (3)
33% (3) — 56% (5) 11% (1) —
Abbreviations: HPV, human papillomavirus; IC, immunocompetent; OTR, organ transplant recipient; RDEB, recessive dystrophic epidermolysis bullosa;
RHA, reverse hybridization assay; SCC, squamous cell carcinoma.
1Shown as a proportion of RHA-positive samples.
Numbers in parentheses indicate number of samples positive.
Table 2. Analysis of viral load for HPV types 5, 8, 15, 23, and 24 in each sample group
Q-PCR positive
Sample group1 Total HPV52 HPV8 HPV15 HPV23 HPV24
OTR SCC (n=13) 38% (5) 75% (3 of 4); 1 per 97,
1 per 883, 1 per 4702
50% (1 of 2);
1 per 4445
14% (1 of 7);
1 per 176
11% (1 of 9);
1 per 30
33% (1 of 3);
1 per 1407
IC SCC (n=7) 29% (2) 50% (1 of 2);
1 per 320
50% (1 of 2);
1 per 80
0 (0) 0 (1) 0 (2)
RDEB SCC (n=12) 25% (3) 50% (1 of 2);
1 per 674
66% (2 of 3); 1 per 15,
1 per 393
0 (4) 17% (1 of 6);
1 per 9
33% (1 of 3);
1 per 79
RDEB peri-lesional skin;
patients with SCC (n=3)
67% (2) 0 (0) 100% (2 of 2); 1 per 38, 1 per 58 0 (0) 0 (2) 0 (2)
RDEB normal skin;
patients without SCC (n=8)
0% 0 (0) 0 (0) 0 (0) 0 (8) 0 (0)
Abbreviations: HPV, human papillomavirus; IC, immunocompetent; OTR, organ transplant recipient; RDEB, recessive dystrophic epidermolysis bullosa;
Q-PCR, quantitative PCR; RHA, reverse hybridization assay; SCC, squamous cell carcinoma.
1Number of samples positive for types 5, 8, 15, 23, or 24 by RHA: note that figures are not additive because of the presence of multiple infections.
2Viral loads were calculated per cell equivalent by normalizing to b-globin.
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with input cell equivalents determined
by normalization to b-globin. HPV b
types were chosen for investigation on
the basis of their frequent detection in
at least two of the three groups of SCC
samples (Table 1). Data are summar-
ized in Table 2. Only 25–38% of the
reverse hybridization assay-positive
SCC samples analyzed were above the
detection threshold for quantitative-
PCR, suggesting that the initial reverse
hybridization assay detection method
was extremely sensitive. The quantita-
tive-PCR detection efficiency in RDEB
SCC was not significantly different
from that reported in a previous study
of predominantly immunocompetent
SCC (Weissenborn et al., 2005), where-
in 46% of samples showed detectable
b-PV viral load (P¼0.248, Fisher’s
exact test). Furthermore, the relative
viral load in the two studies were
very similar, with all SCC showing
comparatively low overall HPV–DNA
copy numbers of less than one per
five cell equivalents. It must be empha-
sized however that these data do not
exclude the possibility of a consider-
ably higher viral load in a subset of
tumor cells, as recently demonstrated
for epidermodysplasia verruciformis
SCC (Dell’Oste et al., 2009). With
the exception of two HPV8-positive
samples where viral load were compar-
able, the RDEB peritumoral and normal
skin samples examined were below the
quantitative-PCR detection threshold.
These combined data imply that high
copy number HPV infection is not a
general feature of RDEB skin, despite its
unique microenvironment. In parti-
cular, RDEB SCC does not appear
significantly different from other cuta-
neous SCC in overall prevalence of
HPV infection or viral load.
To our knowledge, the possible con-
tribution of HPV infection to RDEB–SCC
pathogenesis is previously unreported.
Although our numbers are small, 21 cases
of RDEB SCC is a significant series for this
rare disease and compares favorably with
other examples of analysis in this tumor
group (23 RDEB SCC examined for p53
immunostaining (Slater et al., 1992) and
25 RDEB SCC analyzed for matrix metallo-
proteinase (MMP) immunostaining (Ki-
visaari et al., 2008) for example. The use
of highly sensitive PCR methodology to
detect relatively ubiquitous viral DNA
sequences together with confounding
factors, such as type of tissue analysed,
have yielded conflicting data on HPV
prevalence in organ transplant recipient
versus immunocompetent individuals,
actinic keratosis versus SCC, and normal
skin (Harwood and Proby, 2002; Weis-
senborn et al., 2005; Feltkamp et al.,
2008; Mackintosh et al., 2009). Never-
theless, combined viral load data have
shown that in contrast to a-PV and
cervical cancer, b-PV presence is not
necessary in each tumor cell for main-
tenance of the malignant phenotype,
although this does not preclude a role
for HPV in cutaneous SCC. Our results
from RDEB SCC lie within the range of
other cutaneous SCC data and show no
evidence of HPV contribution to the
increased incidence and aggressive nat-
ure of RDEB SCC.
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